Read this SEC filing. It states: "During the three fiscal years ended March 31, 2005, consolidated net sales have grown from $79.1 million to $93.7 million." Well, that's 8.8% compounded revenue growth -- hardly exciting.
I called CNS (NASDAQ:CNXS) this morning to check the status of the U.S. Patent and Trademark Office's re-examination to two of the company's nasal strip patents. My call was not returned. While the company is certainly the top dog in nasal strips with 93% of the market, any weakening of its patent position might encourage copycats. With operating margins of 23.5%, there's plenty of money to attract competition.
Don't take the patent re-examination lightly. In 2000, the company's primary licensed patent was re-examined and a few claims were rejected.
Here's the final word. Do what insiders are doing. Over the last six months, in 19 separate transactions, they sold 237,439 shares. There were no purchases. Now that's bearish!
Do small-cap stocks producing mounds of cash fit into your portfolio objectives? If so, try this free trial offer from Motley Fool co-founder Tom Gardner and his Motley Fool Hidden Gems newsletter team.
Wait! You're not done. This is just a quarter of the duel! Don't miss the Bull and Bear opening arguments and the Bull rebuttal. Even when you're done, you're still not done. You can vote and let us know who you think won this duel.
Fool contributor W.D. Crotty does not own any shares in the companies mentioned. Click here to see The Motley Fool's disclosure policy.
